


RESEARCH ARTICLE

Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia

Fu-Chun Zhou¹✉, Chuan-Yue Wang¹✉, Gabor S. Ungvari^{2,3}, Chee H. Ng⁴, Yan Zhou¹, Liang Zhang¹, Jingjing Zhou¹, David H. K. Shum⁵, David Man⁶, Deng-Tang Liu⁷, Jun Li^{8,9,10}, Yu-Tao Xiang¹¹*

1 Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China, **2** The University of Notre Dame Australia / Marian Centre, Perth, Australia, **3** School of Psychiatry & Clinical Neurosciences, University of Western Australia, Perth, Australia, **4** Department of Psychiatry, University of Melbourne, Melbourne, Victoria, Australia, **5** Menzies Health Institute Queensland and School of Applied Psychology, Griffith University, Gold Coast, Queensland, Australia, **6** Department of Rehabilitation Sciences, Hong Kong Polytechnic University, Hong Kong SAR, China, **7** Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, **8** State Key Laboratory of Cognitive Neuroscience and Learning, Beijing, China, **9** IDG/McGovern Institute for Brain Research, Beijing, China, **10** Center for Collaboration and Innovation in Brain and Learning Sciences, Beijing Normal University, Beijing, China, **11** Unit of Psychiatry, Faculty of Health Sciences, University of Macau, Macao SAR, China



OPEN ACCESS

Citation: Zhou F-C, Wang C-Y, Ungvari GS, Ng CH, Zhou Y, Zhang L, et al. (2017) Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia. PLoS ONE 12(2): e0172114. doi:10.1371/journal.pone.0172114

Editor: Tifei Yuan, Nanjing Normal University, CHINA

Received: May 28, 2016

Accepted: January 31, 2017

Published: February 28, 2017

Copyright: © 2017 Zhou et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: The Clinical Research Ethics Committee of Beijing Anding Hospital that approved the study prohibits the authors from making the research data set publicly available. If anyone outside the research team wishes to access the dataset, the PI of the project will need to apply for an approval from the Clinical Research Ethics Committee. Readers and all interested researchers may contact Dr. Chuan-Yue Wang (email address: wang.cy@163.net) or the Office Director of Beijing Key Laboratory of Mental Disorders at Beijing Anding Hospital Ms. Wen Wang (email address: wenwang@andinghospital.com).

✉ These authors contributed equally to this work.

* xyutly@gmail.com

Abstract

This study aimed to investigate prospective memory (PM) and the association with clinical factors at 1-year follow-up in first-episode schizophrenia (FES). Thirty-two FES patients recruited from a university-affiliated psychiatric hospital in Beijing and 17 healthy community controls (HCs) were included. Time- and event-based PM (TBPM and EBPM) performances were measured with the Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) at baseline and at one-year follow-up. A number of other neurocognitive tests were also administered. Remission was determined at the endpoint according to the PANSS score ≤ 3 for selected items. Repeated measures analysis of variance revealed a significant interaction between time (baseline vs. endpoint) and group (FES vs. HCs) for EBPM ($F_{(1, 44)} = 8.8, p = 0.005$) and for all neurocognitive components. Paired samples t -tests showed significant improvement in EBPM in FES (13.1 ± 3.7 vs. 10.3 ± 4.8 ; $t = 3.065, p = 0.004$), compared to HCs (15.7 ± 3.6 vs. 16.5 ± 2.3 ; $t = -1.248, p = 0.230$). A remission rate of 59.4% was found in the FES group. Analysis of covariance revealed that remitters performed significantly better on EBPM (14.9 ± 2.6 vs. 10.4 ± 3.6 ; $F_{(1, 25)} = 12.2, p = 0.002$) than non-remitters at study endpoint. The association between EBPM and 12-month clinical improvement in FES suggests that EBPM may be a potential neurocognitive marker for the effectiveness of standard pharmacotherapy. Furthermore, the findings also imply that PM may not be strictly a trait-related endophenotype as indicated in previous studies.

ww0230@sina.com) to help submit potential applications to the Ethics Committee for access to the dataset.

Funding: The study was supported by the following agencies and funds: National Natural Science Foundation of China (Grant No. 81171270, 30800367, 30770776), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201403), Beijing Sciences and Technology Nova Program (Grant No. 2008B59), National Scientific and Technical Supporting Programs of China (Grant No. 2007BAI17B04), and the National High Technology Research and Development Program of China (863 Program. Grant No. 2009AA022702).

Competing interests: The authors have declared that no competing interests exist.

Introduction

Cognitive impairment is a core feature of schizophrenia [1–3]. A broad range of deficits in psychomotor speed, memory, attention, reasoning, and social cognition have been reported [4]. Cognitive deficits usually exist even before the onset of illness [3, 5–8], worsen during the early phase of schizophrenia [9], and persist throughout the whole life of patients, which, in turn, influence functional outcomes [10, 11].

The course and trajectory of neurocognitive deficits in schizophrenia remain unclear. Over time, they may deteriorate, show no significant change or even improve in certain cognitive domains [12, 13]. The discrepancy between studies may be due to the heterogeneity of the illness and the types of treatment [14, 15].

A meta-analysis of longitudinal studies has found that schizophrenia patients showed less improvement over time compared to controls in most cognitive variables except on the Stroop Color-Word Test. These results suggest distinctive trajectories of changes in certain cognitive components [13].

Prospective memory (PM) refers to remembering to perform a planned action or intention at some future point in time [16]. PM is thought to play an important role to maintain daily functioning. PM deficits have been consistently confirmed in both chronic [17–26] and first-episode schizophrenia (FES) [27–29]. Non-psychotic first-degree relatives of schizophrenia patients show similar but attenuated PM impairments compared to patients suggesting that PM deficits may be an endophenotype of the illness [30].

There are two subtypes of PM: time-based (TBPM) and event-based PM (EBPM). In EBPM, the carrying out of an intended action is prompted by an external cue, while TBPM relies on the ability to perform an action at a specified time in the future [31]. PM is related to prefrontal-lobe functions in both schizophrenia patients and their first-degree relatives, but TBPM and EBPM may involve different neurocognitive processes [28, 30].

Longitudinal studies on PM changes in FES are important for a better understanding of the pathophysiology of schizophrenia. Certain critical brain areas, such as the frontal pole, hippocampus, lateral prefrontal and inferior parietal regions, involved in PM impairment, have also been reported to be abnormal in schizophrenia [32–38]. To the best of our knowledge, only one follow-up study tracked PM changes over a one-year period finding that while TBPM impairment was unchanged, EBPM significantly improved at the endpoint [39]. Because the control group was not followed up, the impact of a differential practice effect on the results could not be ruled out. It has been suggested that similar practice effects usually occur in both control and clinical groups [40]. In order to control the potential practice effects, both patient and control groups should be followed up [41].

The present study aimed to examine PM changes at one-year follow-up in both FES and healthy controls, and explore their associations with demographic and clinical characteristics.

Methods

Participants and study setting

The study was conducted between January 2008 and December 2010 at the National Clinical Research Centre of Mental Disorders located in Beijing Anding Hospital, an 800-bed university-affiliated psychiatric center. Age-, gender- and education level-matched controls were recruited from the community via media advertisement.

In- and out-patients receiving treatment for first-episode psychosis were consecutively referred by their treating psychiatrists to the research team for screening of eligibility. Inclusion criteria were (1) age between 16 and 45 years; (2) Chinese ethnicity; (3) at least six years of

education; (4) first episode of the illness; (5) diagnosis of schizophrenia was made according to the DSM-IV (APA, 1994) by two attending psychiatrists who administered the Structural Clinical Interview for DSM-IV (SCID-DSM-IV; First et al., 1996), augmented by a chart review; (6) ability to understand the aims of the study and the contents of the clinical interview and (7) willingness to provide informed consent; (8) either antipsychotic treatment naïve or treatment initiation of less than one month. Patients with a history of drug/alcohol abuse, ECT in the past 12 months, medical or neurological condition(s), or mental retardation were excluded from the study.

The study protocol was approved by the Clinical Research Ethics Committee of Beijing Anding Hospital. Written consent was obtained prior to assessment from patients or their family members for patients younger than 18 years of age as long as they verbally agreed to participate.

Assessment

Basic socio-demographic and clinical characteristics were collected with a standard form designed for this study by reviewing the charts supplemented by a clinical interview conducted by a psychiatrist. Psychopathology was assessed using the Chinese version of the Positive and Negative Syndrome Scale (PANSS; [42]). In this study, the following five clusters of the PANSS were used: 1. Anergia (N1, N2, G7, G10); 2. Thought disturbance (P2, P3, P5, G9); 3. Activation (P4, G4, G5); 4. Paranoid/belligerence (P6, P7, G8); 5. Depression (G1, G2, G3, G6) [43]. Clinical remission was defined by a PANSS score = /<3 on each of the following items at the endpoint of the study: delusions (P1), unusual thought contents (G9), hallucinatory behavior (P3), conceptual disorganization (P2), mannerism/posturing (G5), blunted affect (N1), social withdrawal (N4) and lack of spontaneity (N6) [44, 45].

The locally validated, Chinese version of the Cambridge PM Test (C-CAMPROMPT [46, 47] was used to assess PM functions for all participants. C-CAMPROMPT is an ecologically-valid PM psychometric test that includes three TBPM and three EBPM tasks while performing a few ongoing activities (i.e., a general knowledge quiz or word-finding puzzle) during a 20 minute period. Participants are allowed to use strategies, such as reminders to assist prospective remembering [48]. The C-CAMPROMPT generates scores on all six tasks, each scoring a maximum of 6, thus the sum score ranges from 0 to 36.

Other neuropsychological assessments also included the following retrospective memory and prefrontal lobe functions:

1. The Hopkins Verbal Learning Test-revised, Chinese version (HVLT-R; [49]) has three learning trials (immediate recall) and a delayed recall subtest, for assessing retrospective memory;
2. The Verbal Fluency Test, Chinese version (VFT; [49]) is composed of two character (phonemic) and two category (semantic) tests; the sum of words produced in the two character and two category trials is averaged and recorded separately;
3. The Color Trails Test (CTT; [49]) comprises two parts (CTT-1 and CTT-2), and is a “culture-fair” version of the Trail Making Test (TMT) for assessing sustained visual attention;
4. The Stroop Color Word Test Chinese version (SCWT; [49]) assesses selective attention and cognitive flexibility; the Stroop Color—Word Interference score was used in this study to measure the ability related to the suppression of a habitual response in favor of an unusual one.

Procedures

All FES patients were treated with antipsychotic monotherapy during the one-year study period and only short-term (usually less than one week) injectable haloperidol was allowed in agitated patients. For agitation, anxiety and insomnia, short-acting benzodiazepines were used sparingly. In addition, low dose anticholinergic medication (trihexyphenidyl, maximum 6 mg/day) and propranolol were allowed to treat extrapyramidal side effects for any length of time.

All the cognitive evaluation was conducted in a quiet room in the morning at the hospital. In order to minimize the possibility of order effects, neurocognitive functions other than PM were administered in a randomized order followed by the C-CAMPROMPT. All the cognitive tests including C-CAMPROMPT were administered by a psychiatrist (FCZ) and a research nurse who received training in using these instruments. Psychiatric symptoms were evaluated by four other psychiatrists who were blinded to the patients' performance on the cognitive tasks. The inter-rater reliability exercise of the PANSS subscales yielded satisfactory agreement; the intra-class correlation coefficients (ICC) ranged from 0.83 to 0.86.

Data analysis

All analyses were performed using SPSS Version 20.0. Comparisons between patients and controls, and between clinically remitted patients and those who failed to remit ('remitters' and 'non-remitters', respectively) with regard to clinical variables were conducted by independent sample *t*-test and Chi square test, as appropriate. Paired samples *t*-tests were used to compare the neurocognitive variables including TBPM and EBPM between entry and endpoint in both patients and controls.

Repeated measures analysis of variance (ANOVA) was performed for each cognitive test with group (patient vs. control; remitters vs. non-remitters) as the between-group factor, and time (baseline vs. 1-year) as the within-group factor. Effects of time, group, and the interaction between time and group were examined. Cognitive domains that exhibited significant time*group effects in patients and HCs were also examined using paired samples *t*-tests to investigate longitudinal changes. In addition, analysis of covariance (ANCOVA) was performed in the patient group comparing cognitive performance between remitters and non-remitters at endpoint with age, gender, educational level and baseline PM score as covariates. All statistical tests were two-tailed. Level of significance was set at the 0.05.

Results

Of the 55 FES patients screened for eligibility, 47 fulfilled entry criteria and participated in the study, but only 40 completed all the assessments at baseline. Eight patients did not complete the endpoint assessment due to lack of interest to continue participation. Patients who dropped out did not differ significantly from those who completed the follow-up in terms of age, gender and education level. Only the 32 patients who completed the endpoint assessment at 1-year follow-up were included for analyses.

At baseline, 10 patients were drug-naïve for antipsychotics, while the other 22 patients had received less than 1 month of antipsychotic monotherapy with either risperidone, olanzapine, aripiprazole, quetiapine, or haloperidol. No patients had received anticholinergic medications before the study. Six patients received low dose (0.5mg-1mg daily) lorazepam before the study entry.

Table 1. Comparisons of longitudinal changes between FES patients and controls with respect to PM and other cognitive functions.

	FES (n = 32)							Controls (n = 17)							#Comparison between groups		
	At baseline		At endpoint		Statistics			At baseline		At endpoint		Statistics			Statistics		
	N	%	N	%	χ^2	df	p	N	%	N	%	χ^2	df	p	χ^2	df	p
Male sex	19	59.4	—	—	—	—	—	13	76.5	—	—	—	—	—	1.4	1	0.23
	Mean	SD	Mean	SD	T/Z	df	P	Mean	SD	Mean	SD	T/Z	df	P	F/Z	df	P
Age (years)	26.2	8.1	—	—	—	—	—	25.5	5.6	—	—	—	—	—	-0.5	— ^a	0.61
Education (years)	13.5	2.2	—	—	—	—	—	12.6	2.3	—	—	—	—	—	-1.3	— ^a	0.20
HVLT-R	22.5	6.5	24.4	4.9	-2.5	31	0.02	26.8	5.3	27.3	4.4	-0.5	16	0.60	0.7	1, 44	0.40
CTT-1	56.9	17.4	51.6	14.1	1.8	31	0.09	43.3	15.1	35.4	9.0	1.8	16	0.09	1.2	1, 44	0.67
CTT-2	98.7	54.4	97.3	41.7	-0.2	— ^a	0.87	76.0	20.1	70.7	13.4	-0.9	— ^a	0.37	0.7	1, 44	0.41
SWCT	34.1	9.8	33.6	8.4	0.3	31	0.79	40.1	7.1	41.9	12.8	-0.6	— ^a	0.57	0.3	1, 44	0.58
VFL	2.6	1.0	1.8	1.5	-2.7	— ^a	0.007	3.6	1.7	4.1	2.0	-1.2	— ^a	0.24	8.0	1, 44	0.007
VFC	12.8	3.7	12.5	2.8	0.5	31	0.63	14.0	4.4	14.5	2.3	-0.5	16	0.62	1.5	1, 44	0.23
TBPM	7.9	5.2	9.3	5.3	-2.2	31	0.03	11.5	5.4	12.6	4.7	-0.7	— ^a	0.48	0.1	1, 44	0.74
EBPM	10.3	4.8	13.1	3.7	-3.1	31	0.004	16.5	2.3	15.7	3.6	-1.1	— ^a	0.26	8.8	1, 44	0.005

Note: (1) Results reported in this column (#) include the comparisons between the two groups regarding baseline age, gender, educational level and longitudinal changes in PM and other cognitive functions. (2) For the repeated measures analysis of variance, only the effect of time*group interaction was presented in the table.

^a = Wilcoxon signed rank test; TBPM = time-based prospective memory; EBPM = event-based prospective memory; HVLT-R = Hopkins Verbal Learning Test-Revised Version; VFL = Verbal Fluency Test (letter test); VFC = Verbal Fluency Test (category test); CTT = Color Trails Test; SCWT = Stroop Color Word Test;

doi:10.1371/journal.pone.0172114.t001

Comparison between patients and controls regarding longitudinal changes in PM and other cognitive functions

Table 1 shows the basic demographic and clinical characteristics of the study sample by groups at baseline and endpoint. At baseline, patients performed significantly poorer than controls in TBPM ($F_{(1,44)} = 6.5, p = 0.014$), EBPM ($F_{(1,44)} = 31.6, p < 0.001$), HVLT-R ($F_{(1,44)} = 6.2, p = 0.017$), CTT-1 ($F_{(1,44)} = 8.7, p = 0.005$), SCWT ($F_{(1,44)} = 7.9, p = 0.007$) and VFL ($F_{(1,44)} = 5.7, p = 0.021$) after controlling for age, gender and educational level. At endpoint, patients' score remained significantly lower than controls in TBPM ($F_{(1,44)} = 5.1, p = 0.029$), EBPM ($F_{(1,44)} = 6.3, p = 0.015$), HVLT-R ($F_{(1,44)} = 7.0, p = 0.011$), CTT-1 ($F_{(1,44)} = 18.9, p < 0.001$), CTT-2 ($F_{(1,44)} = 12.4, p = 0.001$), SCWT ($F_{(1,44)} = 8.8, p = 0.005$), VFL ($F_{(1,44)} = 21.4, p < 0.001$) and VFC ($F_{(1,44)} = 13.7, p = 0.001$) after controlling for age, gender and education level.

In the patient group paired samples *t*-tests revealed significant changes from baseline to the endpoint on TBPM, EBPM, HVLT-R and VFL scores. No difference was found between baseline and endpoint assessments in the control group in any of the cognitive performances including TBPM and EBPM.

After controlling for age, gender and education level, results of a repeated measures ANOVA revealed significant time (baseline vs. endpoint)*group (FES vs. HCs) interaction only in EBPM ($F_{(1,44)} = 8.8, p = 0.005$) (Table 1).

The association between clinical outcomes and neurocognitive trajectories

Patients' demographic and clinical characteristics and **neurocognitive performance** by remission status are shown in Table 2 and Figs 1 and 2. At the endpoint, there were 19 (59.4%)

Table 2. Comparison between remitters and non-remitters with respect to demographic, clinical, PM and other cognitive variables at baseline and endpoint.

	At baseline							At endpoint						
	Remitters (n = 19)		Non-remitters (n = 13)		Statistics			Remitters (n = 19)		Non-remitters (n = 13)		Statistics		
	N	%	N	%	χ^2	df	p	N	%	N	%	χ^2	df	p
Male sex	11	57.9	8	61.5	— ^b	—	1.00	—	—	—	—	—	—	—
Inpatients	6	31.6	4	30.8	— ^b	—	1.00	0	0.0	0	0.0	—	—	—
Medication status														
Drug naïve	6	31.6	4	30.8	— ^b	—	1.00	0	0.0	0	0.0	—	—	0.00
risperidone	3	15.8	3	23.1	— ^b	—	0.67	5	26.3	3	23.1	— ^b	—	1.00
olanzapine	0	0.0	1	7.7	— ^b	—	0.40	5	26.3	5	38.5	— ^b	—	0.70
aripiprazole	7	36.8	3	23.1	— ^b	—	0.47	9	47.4	5	38.5	— ^b	—	0.73
quetiapine	2	10.5	0	0.0	— ^b	—	0.50	0	0.0	0	0.0	—	—	0.00
haloperidol	1	5.3	2	15.4	— ^b	—	0.55	0	0.0	0	0.0	—	—	0.00
Concomitant medications														
Anticholinergics	0	0.0	0	0.0	—	—	—	6	31.6	6	46.2	— ^b	—	0.47
Benzodiazepines	3	15.8	3	23.1	— ^b	—	0.67	0	0.0	0	0.0	—	—	—
	Mean	SD	Mean	SD	T/Z	df	P	Mean	SD	Mean	SD	T/Z	df	P
Age (years)	25.2	8.5	27.6	7.5	-1.2	— ^a	0.23	—	—	—	—	—	—	—
Education (years)	13.1	2.4	14.0	1.7	-1.0	— ^a	0.32	—	—	—	—	—	—	—
Duration of illness (months)	8.1	4.6	20.0	11.1	-3.1	— ^a	0.002	—	—	—	—	—	—	—
PANSS subscales														
Positive	27.3	6.9	29.8	6.4	-1.0	30	0.31	7.6	1.3	10.9	4.0	-3.2	— ^a	0.002
Negative	28.1	4.3	25.5	4.1	1.7	30	0.11	9.2	2.9	16.5	5.3	-3.8	— ^a	<0.001
General	41.3	5.63	42.5	6.57	-0.6	30	0.58	18.4	2.3	23.2	4.8	-4.4	16.8	<0.001
PANSS cluster														
Anergia	9.8	3.0	12.1	3.1	-2.1	30	0.04	5.1	1.4	7.8	2.6	-3.4	16.4	0.003
Thought disturbance	13.8	2.8	14.9	2.7	-1.2	30	0.26	4.4	0.8	6.3	2.4	-2.7	— ^a	0.02
Activation	7.2	1.7	6.2	2.4	1.4	30	0.19	3.1	0.5	3.9	1.5	-1.9	— ^a	0.22
Paranoid/belligerence	10.0	1.7	8.8	2.5	1.7	30	0.11	3.1	0.2	4.0	1.5	-2.4	— ^a	0.10
Depression	8.5	2.9	8.7	3.6	-0.2	30	0.85	4.6	1.5	4.8	2.0	-0.1	—	0.94
CPZeq (mg)	67.6	63.4	84.7	84.3	-0.5	— ^a	0.63	267.6	68.6	292.3	81.3	-0.7	— ^a	0.47
HVLT-R	24.6	5.8	19.3	6.3	2.5	30	0.02	25.5	4.9	22.9	4.7	1.6	30	0.13
CTT-1	58.1	19.8	55.2	13.7	0.5	30	0.64	50.6	14.1	53.0	14.6	-0.5	30	0.64
CTT-2	102.6	69.6	93.0	18.2	-0.3	— ^a	0.79	95.8	42.1	99.4	42.7	-0.6	— ^a	0.56
SWCT	35.3	10.5	32.5	8.9	0.8	30	0.44	35.7	6.3	30.5	10.3	1.8	30	0.09
VFL	2.4	0.9	3.0	1.1	-1.6	— ^a	0.12	2.0	1.5	1.4	1.4	-1.0	— ^a	0.33
VFC	13.7	4.0	11.6	3.0	1.6	30	0.12	12.9	2.7	11.9	2.9	1.0	30	0.32
TBPM	10.0	4.9	4.9	4.2	3.1	30	0.005	11.7	4.6	5.7	4.1	3.8	30	<0.001
EBPM	11.3	5.0	8.9	4.2	1.4	30	0.17	14.9	2.6	10.4	3.6	-3.3	— ^a	<0.001

^a = Mann-Whitney U test;

^b = Fisher's Exact Test; PANSS = Positive and Negative Syndrome Scale; TBPM = time-based prospective memory; EBPM = event-based prospective memory; HVLT-R = Hopkins Verbal Learning Test-Revised Version; VFL = Verbal Fluency Test (letter test); VFC = Verbal Fluency Test (category test); CTT = Color Trails Test; SCWT = Stroop Color Word Test; CPZeq = chlorpromazine equivalent

doi:10.1371/journal.pone.0172114.t002

remitters. Compared to non-remitters, remitters had a significantly shorter duration of illness, a better performance on HVLT-R and TBPM, and lower PANSS "Anergia" score at baseline; while having better performance on TBPM and EBPM, lower PANSS "Anergia" and "Thought disturbance" scores at endpoint.




Fig 1. Time-based PM in FES patients and healthy controls.

doi:10.1371/journal.pone.0172114.g001

After controlling for age, gender, educational level, duration of illness and baseline EBPM score, remitters still performed significantly better on EBPM ($F_{(1, 25)} = 12.2, p = 0.002$) than non-remitters at endpoint. However, the difference on TBPM ($F_{(1, 25)} = 3.1, p = 0.09$) scores between remitters and non-remitters disappeared after basic demographic characteristics and the baseline assessments of cognitive functions were controlled for.




Fig 2. Event-based PM in FES patients and healthy controls.

doi:10.1371/journal.pone.0172114.g002

Discussion

To the best of our knowledge, this is the first longitudinal, healthy controlled study on PM in first-episode schizophrenia. The main finding is that EBPM significantly improved over time in FES. Patients who remitted from their first-episode performed significantly better on EBPM than non-remitters at 1-year follow-up suggesting that the improvement in EBPM performance is probably associated with clinical remission in FES. These findings are consistent with those of another longitudinal study that explored changes in PM in FES [39]. In that study, patients' EBPM performance gradually improved over time and eventually showed no significant difference compared to healthy controls at the 1-year assessment. However, the control group was not followed up and tested at 1-year, therefore the practice effect on the results could not be excluded since TBPM deficit remained at the endpoint. In addition, PM was assessed using a dual-task paradigm in the Cheung et al.'s study [39]; i.e., participants needed to execute the PM task at a certain time or on the appearance of certain PM cues. In the present study, ecologically valid paradigms were used. The Cambridge PM Task has the advantage of simulating real-life situations and allowing participants to adopt strategies, such as taking notes as reminders, to facilitate PM performance. Moreover, only the PANSS was used to measure psychopathology in the Cheung et al.'s study; in contrast, both the PANSS and remission using the Andreasen's definition [44, 45] were used in this study. Finally, types and doses of antipsychotics were included in this study.

Neuroimaging studies found that the prefrontal cortex, particularly the lateral and medial parts, plays an important role in generating PM [50–54]. In addition, the left parahippocampal gyrus and the middle temporal gyrus are also activated during PM tasks in PET and fMRI studies [50, 55–57]. Furthermore, both the prefrontal and temporal cortices have been impaired in schizophrenia patients and their first-degree relatives [58, 59]. Taken together, these findings suggest that impairments of PM might be an endophenotype of schizophrenia. Endophenotypes are considered as “quantifiable biological variations or deficits that are types of stable trait markers or indicators of presumed inherited vulnerability or liability to a disease” [60]. However, the relative stability does not mean that the endophenotype could not be changed in response to treatment. In clinical practice the primary focus is not to modify the genetic variations associated with the endophenotype, but to “normalize” neural circuits and activate collateral circuits [61], which may play a role in restoring neurocognitive and neurophysiological functions.

Findings on the trajectory of neurocognitive functioning in schizophrenia are inconsistent. For example, verbal memory and learning were reported to be worsened, unchanged, or improved across different studies [62–67]. In one study, there was a significant decline in Verbal Learning and improvement on Reasoning/Problem Solving and Social Cognition at 2-year follow-up in FES patients, but not in the control group, indicating a different neurocognitive trajectory [68].

The inconsistency of the findings may reflect the involvement of different neural circuits in cognitive processes. There have been several neuroimaging and neuropsychological studies on the neural circuits possibly involved in TBPM and EBPM. A positron emission tomography (PET) study has found the activation differences in rostral prefrontal cortex between TBPM and EBPM tasks [56]. Specifically, when carrying out TBPM tasks, participants showed more activation in areas of left superior frontal gyrus, right superior frontal gyrus, anterior medial frontal lobe and anterior cingulate gyrus. When carrying out EBPM tasks, a different region in the left superior frontal gyrus was found to be more active. Using the human lesion approach, Volle et al. (2011) found that TBPM deficit in both words and pictures was specifically associated with lesions in the right polar prefrontal region, which was not due to impairments in

basic neurocognitive functions. TBPM and EBPM may involve different frontal lobe processing in FES; specifically, TBPM was found to be independently associated with CTT-2 and WCST-CC, whereas EBPM was found to be predicted by WCST-PE [28].

It is thought that TBPM requires self-initiated retrieval and places greater demand on the prefrontal cortex than EBPM [69]. This assumption was confirmed through moderator analysis in a meta-analysis [70], showing that the variances were heterogeneous between TBPM and EBPM; TBPM being more impaired than EBPM in schizophrenia. In a longitudinal study only TBPM predicted remission after 8-week treatment pointing to the possible role of TBPM in the short-term outcome of FES [71].

EBPM exhibited greater improvement in patients than in controls, while TBPM remained impaired in patients, which is consistent with earlier findings [39]. In addition, the present study found that remission is positively associated with better EBPM performance. These results may have the following theoretical and clinical implications: (1) TBPM impairment is relatively stable suggesting that it is more likely to be an endophenotype and associated to genetic disposition; (2) EBPM could be potentially a neurocognitive marker of treatment response in first episode schizophrenia.

The strengths of this study include the use of standardized assessment of PM, widely accepted criteria of remission and standardized antipsychotic monotherapy. However, the results should be interpreted with caution due to the following methodological limitations. First, only a third of patients were drug-naïve at baseline and some patients received anticholinergics or benzodiazepines. Second, the 1-year study period is relatively short; therefore, longer term emerging changes in cognitive components could not be detected. Third, the sample size was relatively small, which limited the statistical power. Fourth, ideally a control group of psychotropic drug-naïve first-episode schizophrenia patients should be included in the one-year follow-up. However, this would have been clinically impossible and unethical. Fifth, due to logistic reasons, neuroimaging and electrophysiological measures were not included in this study. Finally, the types and doses of antipsychotic medications used in the study period were not fixed, which might have influenced the clinical outcomes. In order to examine the underlying neural circuits associated with PM changes in schizophrenia, longitudinal studies with fixed-dose antipsychotic monotherapy should be conducted coupled with extended follow-up and neuroimaging and electrophysiological measures.

In conclusion, at 1-year follow-up, only EBPM improvement was associated with clinical remission suggesting that it may be a potential neurocognitive marker for treatment response. PM is likely to be a heterogeneous cognitive function both from theoretical and clinical viewpoints in that TBPM appears to be a trait-related endophenotype, while EBPM may possibly be a state-related component of PM.

Acknowledgments

The study was supported by the following agencies and funds: National Natural Science Foundation of China (Grant No. 81171270, 30800367, 30770776), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201403), Beijing Sciences and Technology Nova Program (Grant No. 2008B59), National Scientific and Technical Supporting Programs of China (Grant No. 2007BAI17B04), and the National High Technology Research and Development Program of China (863 Program. Grant No. 2009AA022702). No investigator benefited from participating in this study. The authors are grateful to Barbara A. Wilson, Hazel Emslie, Jennifer Foley, Agnes Shiel, Peter Watson, Kari Hawkins, Yvonne Groot and Jonathan J. Evans, who allowed us to use the CAMPROMT in this study.

Author Contributions

Conceptualization: FCZ CYW GSU YTX.

Data curation: FCZ YZ LZ.

Formal analysis: FCZ YZ LZ.

Funding acquisition: CYW YTX.

Investigation: FCZ YZ LZ JZ.

Methodology: FCZ DHKS DM.

Project administration: CYW YTX.

Resources: CYW.

Software: FCZ YZ LZ.

Supervision: CYW YTX.

Validation: CYW.

Visualization: FCZ.

Writing – original draft: FCZ GSU YTX.

Writing – review & editing: CHN DHKS DM DTL JL.

References

1. Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. *Neuropsychol Rev.* 2005; 15(2):73–95. Epub 2005/10/08. doi: [10.1007/s11065-005-6254-9](https://doi.org/10.1007/s11065-005-6254-9) PMID: [16211467](https://pubmed.ncbi.nlm.nih.gov/16211467/)
2. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology.* 1998; 12(3):426–45. Epub 1998/07/23. PMID: [9673998](https://pubmed.ncbi.nlm.nih.gov/9673998/)
3. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology.* 2009; 23(3):315–36. Epub 2009/05/06. doi: [10.1037/a0014708](https://doi.org/10.1037/a0014708) PMID: [19413446](https://pubmed.ncbi.nlm.nih.gov/19413446/)
4. Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, et al. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. *J Clin Psychiatry.* 2009; 70 Suppl 1:4–46. Epub 2009/03/21.
5. Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, et al. Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. *Am J Psychiatry.* 2005; 162(1):71–8. Epub 2004/12/31. doi: [10.1176/appi.ajp.162.1.71](https://doi.org/10.1176/appi.ajp.162.1.71) PMID: [15625204](https://pubmed.ncbi.nlm.nih.gov/15625204/)
6. Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, Lieberman JA. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. *Schizophr Res.* 2006; 88(1–3):26–35. Epub 2006/08/26. doi: [10.1016/j.schres.2006.06.041](https://doi.org/10.1016/j.schres.2006.06.041) PMID: [16930949](https://pubmed.ncbi.nlm.nih.gov/16930949/)
7. Reichenberg A, Weiser M, Caspi A, Knobler HY, Lubin G, Harvey PD, et al. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. *J Clin Exp Neuropsychol.* 2006; 28(2):193–207. Epub 2006/02/18. doi: [10.1080/13803390500360372](https://doi.org/10.1080/13803390500360372) PMID: [16484093](https://pubmed.ncbi.nlm.nih.gov/16484093/)
8. Whyte MC, Brett C, Harrison LK, Byrne M, Miller P, Lawrie SM, et al. Neuropsychological performance over time in people at high risk of developing schizophrenia and controls. *Biol Psychiatry.* 2006; 59(8):730–9. Epub 2006/01/04. doi: [10.1016/j.biopsych.2005.08.028](https://doi.org/10.1016/j.biopsych.2005.08.028) PMID: [16388781](https://pubmed.ncbi.nlm.nih.gov/16388781/)
9. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. *AJ Psychiatry.* 2000; 157(4):549–59. Epub 2000/03/30.
10. Matza LS, Buchanan R, Purdon S, Brewster-Jordan J, Zhao Y, Revicki DA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. *Schizophr Bull.* 2006; 32(4):666–78. Epub 2006/07/11. doi: [10.1093/schbul/sbl004](https://doi.org/10.1093/schbul/sbl004) PMID: [16829550](https://pubmed.ncbi.nlm.nih.gov/16829550/)

11. Rodriguez-Sanchez JM, Ayesa-Arriola R, Perez-Iglesias R, Perianez JA, Martinez-Garcia O, Gomez-Ruiz E, et al. Course of cognitive deficits in first episode of non-affective psychosis: a 3-year follow-up study. *Schizophr Res*. 2013; 150(1):121–8. Epub 2013/08/01. doi: [10.1016/j.schres.2013.06.042](https://doi.org/10.1016/j.schres.2013.06.042) PMID: [23899999](https://pubmed.ncbi.nlm.nih.gov/23899999/)
12. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. *Schizophr Res*. 2005; 74(1):15–26. Epub 2005/02/08. doi: [10.1016/j.schres.2004.07.005](https://doi.org/10.1016/j.schres.2004.07.005) PMID: [15694750](https://pubmed.ncbi.nlm.nih.gov/15694750/)
13. Szoke A, Trandafir A, Dupont ME, Meary A, Schurhoff F, Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. *Br J Psychiatry*. 2008; 192(4):248–57. Epub 2008/04/02. doi: [10.1192/bjp.bp.106.029009](https://doi.org/10.1192/bjp.bp.106.029009) PMID: [18378982](https://pubmed.ncbi.nlm.nih.gov/18378982/)
14. Seaton BE, Goldstein G, Allen DN. Sources of heterogeneity in schizophrenia: the role of neuropsychological functioning. *Neuropsychol Rev*. 2001; 11(1):45–67. Epub 2001/06/08. PMID: [11392562](https://pubmed.ncbi.nlm.nih.gov/11392562/)
15. Takahashi S. Heterogeneity of schizophrenia: Genetic and symptomatic factors. *Am J Med Genet B Neuropsychiatr Genet*. 2013; 162B(7):648–52. Epub 2013/10/18. doi: [10.1002/ajmg.b.32161](https://doi.org/10.1002/ajmg.b.32161) PMID: [24132896](https://pubmed.ncbi.nlm.nih.gov/24132896/)
16. McDaniel MA, Einstein GO. Prospective memory: An overview and synthesis of an emerging field: Sage Publications; 2007.
17. Altgassen M, Kliegel M, Rendell P, Henry JD, Zolig J. Prospective memory in schizophrenia: the impact of varying retrospective-memory load. *J Clin Exp Neuropsychol*. 2008; 30(7):777–88. Epub 2008/07/09. doi: [10.1080/13803390701779552](https://doi.org/10.1080/13803390701779552) PMID: [18608664](https://pubmed.ncbi.nlm.nih.gov/18608664/)
18. Chan RC, Wang Y, Ma Z, Hong XH, Yuan Y, Yu X, et al. Objective measures of prospective memory do not correlate with subjective complaints in schizophrenia. *Schizophr Res*. 2008; 103(1–3):229–39. doi: [10.1016/j.schres.2008.02.019](https://doi.org/10.1016/j.schres.2008.02.019) PMID: [18420383](https://pubmed.ncbi.nlm.nih.gov/18420383/)
19. Elvevag B, Maylor EA, Gilbert AL. Habitual prospective memory in schizophrenia. *BMC psychiatry*. 2003; 3:9. doi: [10.1186/1471-244X-3-9](https://doi.org/10.1186/1471-244X-3-9) PMID: [12890293](https://pubmed.ncbi.nlm.nih.gov/12890293/)
20. Henry JD, Rendell PG, Kliegel M, Altgassen M. Prospective memory in schizophrenia: primary or secondary impairment? *Schizophr Res*. 2007; 95(1–3):179–85. doi: [10.1016/j.schres.2007.06.003](https://doi.org/10.1016/j.schres.2007.06.003) PMID: [17630257](https://pubmed.ncbi.nlm.nih.gov/17630257/)
21. Shum D, Ungvari GS, Tang WK, Leung JP. Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks. *Schizophr Bull*. 2004; 30(4):693–701. PMID: [15954184](https://pubmed.ncbi.nlm.nih.gov/15954184/)
22. Twamley EW, Woods SP, Zurhellen CH, Vertinski M, Narvaez JM, Mausbach BT, et al. Neuropsychological substrates and everyday functioning implications of prospective memory impairment in schizophrenia. *Schizophr Res*. 2008; 106(1):42–9. doi: [10.1016/j.schres.2007.10.030](https://doi.org/10.1016/j.schres.2007.10.030) PMID: [18055178](https://pubmed.ncbi.nlm.nih.gov/18055178/)
23. Ungvari GS, Xiang YT, Tang WK, Shum D. Prospective memory and its correlates and predictors in schizophrenia: an extension of previous findings. *Archives of clinical neuropsychology: the official journal of the National Academy of Neuropsychologists*. 2008; 23(5):613–22.
24. Wang Y, Chan RC, Hong X, Ma Z, Yang T, Guo L, et al. Prospective memory in schizophrenia: further clarification of nature of impairment. *Schizophr Res*. 2008; 105(1–3):114–24. doi: [10.1016/j.schres.2008.07.002](https://doi.org/10.1016/j.schres.2008.07.002) PMID: [18707848](https://pubmed.ncbi.nlm.nih.gov/18707848/)
25. Wang Y, Chan RC, Xin Y, Shi C, Cui J, Deng Y. Prospective memory deficits in subjects with schizophrenia spectrum disorders: a comparison study with schizophrenic subjects, psychometrically defined schizotypal subjects, and healthy controls. *Schizophr Res*. 2008; 106(1):70–80. doi: [10.1016/j.schres.2007.07.020](https://doi.org/10.1016/j.schres.2007.07.020) PMID: [17719206](https://pubmed.ncbi.nlm.nih.gov/17719206/)
26. Woods SP, Twamley EW, Dawson MS, Narvaez JM, Jeste DV. Deficits in cue detection and intention retrieval underlie prospective memory impairment in schizophrenia. *Schizophr Res*. 2007; 90(1–3):344–50. doi: [10.1016/j.schres.2006.11.005](https://doi.org/10.1016/j.schres.2006.11.005) PMID: [17175138](https://pubmed.ncbi.nlm.nih.gov/17175138/)
27. Lui SS, Wang Y, Yang TX, Liu AC, Chui WW, Yeung HK, et al. Problems in remembering to carry out future actions in first-episode schizophrenia: primary or secondary impairment? *J Psychiatr Res*. 2015; 61:141–9. Epub 2014/12/07. doi: [10.1016/j.jpsychires.2014.11.007](https://doi.org/10.1016/j.jpsychires.2014.11.007) PMID: [25479767](https://pubmed.ncbi.nlm.nih.gov/25479767/)
28. Zhou FC, Xiang YT, Wang CY, Dickerson F, Au RW, Zhou JJ, et al. Characteristics and clinical correlates of prospective memory performance in first-episode schizophrenia. *Schizophr Res*. 2012; 135(1–3):34–9. Epub 2012/01/10. doi: [10.1016/j.schres.2011.12.001](https://doi.org/10.1016/j.schres.2011.12.001) PMID: [22222379](https://pubmed.ncbi.nlm.nih.gov/22222379/)
29. Zhuo K, Lu Y, Yang Z, Fan X, Song Z, Liao L, et al. Prospective memory performance in patients with drug-naïve, first-episode psychosis. *Schizophr Res*. 2013; 143(2–3):285–90. Epub 2012/12/27. doi: [10.1016/j.schres.2012.12.002](https://doi.org/10.1016/j.schres.2012.12.002) PMID: [23267733](https://pubmed.ncbi.nlm.nih.gov/23267733/)
30. Zhou FC, Hou WM, Wang CY, Ungvari GS, Chiu HF, Correll CU, et al. Prospective memory performance in non-psychotic first-degree relatives of patients with schizophrenia: a controlled study. *PLoS one*. 2014; 9(11):e111562. Epub 2014/11/05. doi: [10.1371/journal.pone.0111562](https://doi.org/10.1371/journal.pone.0111562) PMID: [25365028](https://pubmed.ncbi.nlm.nih.gov/25365028/)
31. Einstein GO, McDaniel MA. Normal aging and prospective memory. *J Exp Psychol Learn Mem Cogn*. 1990; 16(4):717–26. PMID: [2142956](https://pubmed.ncbi.nlm.nih.gov/2142956/)

32. Boos HB, Aleman A, Cahn W, Hulshoff Pol H, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. *Arch Gen Psychiatry*. 2007; 64(3):297–304. Epub 2007/03/07. doi: [10.1001/archpsyc.64.3.297](https://doi.org/10.1001/archpsyc.64.3.297) PMID: [17339518](https://pubmed.ncbi.nlm.nih.gov/17339518/)
33. Burgess PW, Quayle A, Frith CD. Brain regions involved in prospective memory as determined by positron emission tomography. *Neuropsychologia*. 2001; 39(6):545–55. PMID: [11257280](https://pubmed.ncbi.nlm.nih.gov/11257280/)
34. Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. *AJ Psychiatry*. 2005; 162(12):2233–45. Epub 2005/12/07.
35. Martin T, McDaniel MA, Guynn MJ, Houck JM, Woodruff CC, Bish JP, et al. Brain regions and their dynamics in prospective memory retrieval: a MEG study. *International Journal of Psychophysiology*. 2007; 64(3):247–58. doi: [10.1016/j.ijpsycho.2006.09.010](https://doi.org/10.1016/j.ijpsycho.2006.09.010) PMID: [17126436](https://pubmed.ncbi.nlm.nih.gov/17126436/)
36. McIntosh AM, Owens DC, Moorhead WJ, Whalley HC, Stanfield AC, Hall J, et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. *Biol Psychiatry*. 2011; 69(10):953–8. Epub 2010/12/21. doi: [10.1016/j.biopsych.2010.11.003](https://doi.org/10.1016/j.biopsych.2010.11.003) PMID: [21168123](https://pubmed.ncbi.nlm.nih.gov/21168123/)
37. Meda SA, Giuliani NR, Calhoun VD, Jagannathan K, Schretlen DJ, Pulver A, et al. A large scale (N = 400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry. *Schizophr Res*. 2008; 101(1–3):95–105. Epub 2008/04/02. doi: [10.1016/j.schres.2008.02.007](https://doi.org/10.1016/j.schres.2008.02.007) PMID: [18378428](https://pubmed.ncbi.nlm.nih.gov/18378428/)
38. Reynolds JR, West R, Braver T. Distinct neural circuits support transient and sustained processes in prospective memory and working memory. *Cereb Cortex*. 2009; 19(5):1208–21. Epub 2008/10/16. doi: [10.1093/cercor/bhn164](https://doi.org/10.1093/cercor/bhn164) PMID: [18854581](https://pubmed.ncbi.nlm.nih.gov/18854581/)
39. Cheung EF, Lui SS, Wang Y, Yang T-x, Shum DH, Chan RC. Time-based but not event-based prospective memory remains impaired one year after the onset of schizophrenia: A prospective study. *Schizophr Res*. 2015; 169(1):147–52.
40. WILSON BA, WATSON PC, BADDELEY AD, EMSLIE H, EVANS JJ. Improvement or simply practice? The effects of twenty repeated assessments on people with and without brain injury. *Journal of the International Neuropsychological Society*. 2000; 6(4):469–79. PMID: [10902416](https://pubmed.ncbi.nlm.nih.gov/10902416/)
41. Slade P, Sanchez P, Townes B, Aldea GS. The use of neurocognitive tests in evaluating the outcome of cardiac surgery: some methodologic considerations. *Journal of Cardiothoracic and Vascular Anesthesia*. 2001; 15(1):4–8. doi: [10.1053/jcan.2001.20284](https://doi.org/10.1053/jcan.2001.20284) PMID: [11254831](https://pubmed.ncbi.nlm.nih.gov/11254831/)
42. He YL, Zhang MY. The positive and negative syndrome scale (PANSS) and its application (in Chinese). *J Clin Psychiatry*. 1997; 7:353–5.
43. Kay SR. Positive and negative syndromes in schizophrenia: assessment and research: Psychology Press; 1991.
44. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. *American Journal of Psychiatry*. 2005; 162(3):441. doi: [10.1176/appi.ajp.162.3.441](https://doi.org/10.1176/appi.ajp.162.3.441) PMID: [15741458](https://pubmed.ncbi.nlm.nih.gov/15741458/)
45. Schennach-Wolff R, Jager M, Mayr A, Meyer S, Kuhn KU, Klingberg S, et al. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients—Is it all about early response? *European Neuropsychopharmacology*. 2011.
46. Lou ZL, Dou ZL, Zheng JL, Y.B. C, Man DWK. The Study of The Chinese version of Cambridge Prospective Memory Test (CAMPROPT) for traumatic brain injury (unpublished Master thesis). Sun Yat Sen University, Guangzhou, P.R. China2009.
47. Man DW, Chan MK, Yip CC. Validation of the Cambridge Prospective Memory Test (Hong Kong Chinese version) for people with stroke. *Neuropsychol Rehabil*. 2015:1–18.
48. Wilson BA, Emslie H, Foley J, Shiel A, Watson P, Hawkins K. Cambridge Prospective Memory Test (CAMPROPT). Assessment H, editor. London: Harcourt Assessment; 2005.
49. Shi C. Neuropsychological Feasibility Study among HIV+/AIDS Subjects in China (in Chinese). *Chinese Mental Health Journal*. 2005; 19:343.
50. Burgess PW, Quayle A, Frith CD. Brain regions involved in prospective memory as determined by positron emission tomography. *Neuropsychologia*. 2001; 39(6):545–55. PMID: [11257280](https://pubmed.ncbi.nlm.nih.gov/11257280/)
51. Burgess PW, Scott SK, Frith CD. The role of the rostral frontal cortex (area 10) in prospective memory: a lateral versus medial dissociation. *Neuropsychologia*. 2003; 41(8):906–18. PMID: [12667527](https://pubmed.ncbi.nlm.nih.gov/12667527/)
52. Burgess PW. On the role of rostral prefrontal cortex (area 10) in prospective memory: University of Cambridge; 2007.
53. Simons JS, Schölvinc ML, Gilbert SJ, Frith CD, Burgess PW. Differential components of prospective memory?: Evidence from fMRI. *Neuropsychologia*. 2006; 44(8):1388–97. doi: [10.1016/j.neuropsychologia.2006.01.005](https://doi.org/10.1016/j.neuropsychologia.2006.01.005) PMID: [16513147](https://pubmed.ncbi.nlm.nih.gov/16513147/)

54. Chen X-j, Wang Y, Wang Y, Yang T-x, Zou L-q, Huang J, et al. Neural correlates of prospective memory impairments in schizophrenia. *Neuropsychology*. 2016; 30(2):169. doi: [10.1037/neu0000225](https://doi.org/10.1037/neu0000225) PMID: [26237628](https://pubmed.ncbi.nlm.nih.gov/26237628/)
55. Reynolds JR, West R, Braver T. Distinct neural circuits support transient and sustained processes in prospective memory and working memory. *Cerebral Cortex*. 2009; 19(5):1208–21. doi: [10.1093/cercor/bhn164](https://doi.org/10.1093/cercor/bhn164) PMID: [18854581](https://pubmed.ncbi.nlm.nih.gov/18854581/)
56. Okuda J, Fujii T, Ohtake H, Tsukiura T, Yamadori A, Frith CD, et al. Differential involvement of regions of rostral prefrontal cortex (Brodmann area 10) in time- and event-based prospective memory. *International Journal of Psychophysiology*. 2007; 64(3):233–46. doi: [10.1016/j.ijpsycho.2006.09.009](https://doi.org/10.1016/j.ijpsycho.2006.09.009) PMID: [17126435](https://pubmed.ncbi.nlm.nih.gov/17126435/)
57. Kiehl KA, Laurens KR, Duty TL, Forster BB, Liddle PF. Neural sources involved in auditory target detection and novelty processing: An event-related fMRI study. *Psychophysiology*. 2001; 38(1):133–42. PMID: [11321614](https://pubmed.ncbi.nlm.nih.gov/11321614/)
58. Boos H, Aleman A, Cahn W, Pol HH, Kahn RS. Brain volumes in relatives of patients with schizophrenia: a meta-analysis. *Archives of General Psychiatry*. 2007; 64(3):297. doi: [10.1001/archpsyc.64.3.297](https://doi.org/10.1001/archpsyc.64.3.297) PMID: [17339518](https://pubmed.ncbi.nlm.nih.gov/17339518/)
59. McIntosh AM, Owens DC, Moorhead WJ, Whalley HC, Stanfield AC, Hall J, et al. Longitudinal volume reductions in people at high genetic risk of schizophrenia as they develop psychosis. *Biological psychiatry*. 2011; 69(10):953–8. doi: [10.1016/j.biopsych.2010.11.003](https://doi.org/10.1016/j.biopsych.2010.11.003) PMID: [21168123](https://pubmed.ncbi.nlm.nih.gov/21168123/)
60. Ritsner MS, Gottesman II. Where do we stand in the quest for neuropsychiatric biomarkers and endophenotypes and what next? *The handbook of neuropsychiatric biomarkers, endophenotypes and genes*: Springer; 2009. p. 3–21.
61. Swerdlow NR. Are we studying and treating schizophrenia correctly? *Schizophr Res*. 2011; 130(1):1–10.
62. Albus M, Hubmann W, Mohr F, Hecht S, Hinterberger-Weber P, Seitz N-N, et al. Neurocognitive functioning in patients with first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2006; 256(7):442–51. doi: [10.1007/s00406-006-0667-1](https://doi.org/10.1007/s00406-006-0667-1) PMID: [17031490](https://pubmed.ncbi.nlm.nih.gov/17031490/)
63. Crespo-Facorro B, Rodriguez-Sanchez JM, Perez-Iglesias R, Mata I, Ayasa R, Ramirez-Bonilla M, et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. *The Journal of clinical psychiatry*. 2009; 70(5):717–29. doi: [10.4088/JCP.08m04634](https://doi.org/10.4088/JCP.08m04634) PMID: [19389335](https://pubmed.ncbi.nlm.nih.gov/19389335/)
64. Hill SK, Schuepbach D, Herbener ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naïve patients with schizophrenia. *Schizophr Res*. 2004; 68(1):49–63. doi: [10.1016/S0920-9964\(03\)00213-5](https://doi.org/10.1016/S0920-9964(03)00213-5) PMID: [15037339](https://pubmed.ncbi.nlm.nih.gov/15037339/)
65. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. *Schizophr Res*. 2005; 78(1):27–34. doi: [10.1016/j.schres.2005.05.010](https://doi.org/10.1016/j.schres.2005.05.010) PMID: [15964177](https://pubmed.ncbi.nlm.nih.gov/15964177/)
66. Leeson VC, Sharma P, Harrison M, Ron MA, Barnes TR, Joyce EM. IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study. *Schizophr Bull*. 2011; 37(4):768–77. doi: [10.1093/schbul/sbp143](https://doi.org/10.1093/schbul/sbp143) PMID: [19934212](https://pubmed.ncbi.nlm.nih.gov/19934212/)
67. Rodríguez-Sánchez JM, Pérez-Iglesias R, González-Blanch C, Pelayo-Terán JM, Mata I, Martínez O, et al. 1-year follow-up study of cognitive function in first-episode non-affective psychosis. *Schizophr Res*. 2008; 104(1):165–74.
68. Torgalsbøen A-K, Mohn C, Czajkowski N, Rund BR. Relationship between neurocognition and functional recovery in first-episode schizophrenia: Results from the second year of the Oslo multi-follow-up study. *Psychiatry Res*. 2015; 227(2):185–91.
69. Einstein GO, McDaniel MA, Richardson SL, Guynn MJ, Cunfer AR. Aging and prospective memory: examining the influences of self-initiated retrieval processes. *Journal of Experimental Psychology: Learning, Memory, and Cognition*. 1995; 21(4):996. PMID: [7673871](https://pubmed.ncbi.nlm.nih.gov/7673871/)
70. Wang Y, Cui J, Chan RC, Deng Y, Shi H, Hong X, et al. Meta-analysis of prospective memory in schizophrenia: nature, extent, and correlates. *Schizophr Res*. 2009; 114(1):64–70.
71. Zhou FC, Xiang YT, Wang CY, Dickerson F, Kreyenbuhl J, Ungvari GS, et al. Predictive value of prospective memory for remission in first-episode schizophrenia. *Perspect Psychiatr Care*. 2014; 50(2):102–10. Epub 2013/12/07. doi: [10.1111/ppc.12027](https://doi.org/10.1111/ppc.12027) PMID: [24308894](https://pubmed.ncbi.nlm.nih.gov/24308894/)